MorphoSys Value Stock - Dividend - Research Selection
MorphoSys
ISIN: DE0006632003, WKN: 663200
Market price: 18,50 EUR
MorphoSys Fundamental data and company key figures of the share
| Annual reports in EUR | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | 27-03-2022 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | -481.445.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | -3.810.210 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | -485.255.200 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | 244.876.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | 2.556.250.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | -514.460.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | -15,400 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | 34.148.800 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | 179.612.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | MOR.XETRA |
| Market Capitalization | 766.225.344,00 USD |
| Country | Germany |
| Indices | CDAX,HDAX,Prime All Share,SDAX,TecDAX |
| Sectors | Biotechnology |
| Raw Data Source | IFRS in Millionen EUR |
| Stock Split | 2008-12-23,3.0000/1.0000 |
| Internet | www.morphosys.de |
Description of the company
Morphosys AG is a German biotechnology company focused on generation of fully human antibodies. It operates two business segments: Partnered Discovery and Proprietary Development. The Partnered Discovery business segment comprises technologies for the generation of human antibody therapeutics, which is exploited via partnerships with multiple pharmaceutical and biotechnology companies. The Proprietary Development business segment involves all activities relating to proprietary therapeutic antibody development, primarily including three main compounds in the Company's proprietary product portfolio, MOR103, MOR202 and MOR208, as well as five programs in the discovery phase and two pre-development programs with Novartis. On January 10, 2013, it announced the completion of the divestment of the AbD Serotec segment, which was engaged in the design and manufacture of antibodies for research and diagnostic purposes, including the Human Combinatorial Antibody Library ( HuCAL) technology